Companies › Stemline Therapeutics
4 active drug programs in 34 registered trials: 16 Phase 2, 14 Phase 1, 4 Phase 3; Oncology; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Elacestrant Estrogen receptor alpha degrader | ESR1 | Phase 3 | Breast Cancer; Metastatic Breast Cancer; Breast Neoplasms; Advanced Breast Cancer … | Nov 2026 |
| Tagraxofusp Interleukin-3 receptor subunit alpha binding agent; Elongation factor 2 inhibitor | IL3RA, EEF2 | Phase 2 | Acute Myeloid Leukemia; Blastic Plasmacytoid Dendritic Cell Neoplasm; Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN); Myelofibrosis … | Feb 2028 |
| MEN2312 KAT6 inhibitor | KAT6 | Phase 1 | Advanced Breast Cancer | Oct 2027 |
| MEN2501 | – | Phase 1 | Platinum-resistant Ovarian Cancer | Dec 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05596409 | Elacestrant | Phase 2 | Metastatic Breast Cancer | Oncology | Nov 2026 |
| NCT06691035 | Elacestrant | Phase 1 | Breast Cancer Metastatic Breast Cancer | Oncology | Nov 2026 |
| NCT05233618 | Tagraxofusp | Phase 1 | Myelofibrosis | Oncology | Dec 2026 |
| NCT05386108 | Elacestrant | Phase 1 | Breast Neoplasms | Oncology | Dec 2026 |
| NCT05982093 | Elacestrant | Phase 2 | Breast Cancer | Oncology | Dec 2026 |
| NCT05563220 | Elacestrant | Phase 1 | Breast Cancer | Oncology | Dec 2026 |
| NCT04216524 | Tagraxofusp | Phase 2 | Blastic Plasmacytoid Dendritic Cell Neoplasm | Oncology | Dec 2026 |
| NCT07159451 | Elacestrant | Phase 2 | Breast Cancer | Oncology | Jan 2027 |
| NCT05038592 | Tagraxofusp | Phase 1 | Chronic Myelomonocytic Leukemia | Oncology | Jan 2027 |
| NCT06498973 | Tagraxofusp | Phase 1 | Acute Myeloid Leukemia | Oncology | Apr 2027 |
| NCT03113643 | Tagraxofusp | Phase 1 | Acute Myeloid Leukemia | Oncology | May 2027 |
| NCT07467772 | Elacestrant | Phase 2 | Uterine Sarcoma | Oncology | Jul 2027 |
| NCT06382948 | Elacestrant | Phase 3 | Advanced Breast Cancer | Oncology | Sep 2027 |
| NCT06923527 | Elacestrant | Phase 2 | ER+ Breast Cancer | Oncology | Sep 2027 |
| NCT06561152 | Tagraxofusp | Phase 1 | Refractory Acute Myeloid Leukemia | Oncology | Oct 2027 |
| NCT06638307 | MEN2312 | Phase 1 | Advanced Breast Cancer | Oncology | Oct 2027 |
| NCT05476770 | Tagraxofusp | Phase 1 | Hematologic Malignancy | Oncology | Nov 2027 |
| NCT07226427 | MEN2501 | Phase 1 | Platinum-resistant Ovarian Cancer | Oncology | Dec 2027 |
| NCT06456463 | Tagraxofusp | Phase 2 | Acute Myeloid Leukemia | Oncology | Feb 2028 |
| NCT07198724 | Elacestrant | Phase 1 | Metastatic Breast Cancer | Oncology | Jun 2028 |
| NCT06062498 | Elacestrant | Phase 2 | Estrogen-receptor-positive Breast Cancer | Oncology | Jul 2028 |
| NCT07209449 | Elacestrant | Phase 2 | Endometrial Cancer | Oncology | Oct 2028 |
| NCT07766018 | Elacestrant | Phase 2 | Breast Cancer | Oncology | Oct 2028 |
| NCT06075953 | Elacestrant | Phase 2 | Ductal Carcinoma in Situ | Oncology | Nov 2028 |
| NCT07007052 | Tagraxofusp | Phase 2 | Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | Oncology | Dec 2028 |
| NCT07395336 | Elacestrant | Phase 2 | Breast Cancer | Oncology | Dec 2028 |
| NCT06201234 | Elacestrant | Phase 2 | Hormone Receptor Positive HER-2 Negative Breast Cancer | Oncology | Dec 2028 |
| NCT07148180 | Tagraxofusp | Phase 1 | Acute Myeloid Leukaemia (AML) | Oncology | Dec 2028 |
| NCT07612215 | Elacestrant | Phase 1 | ER Positive, HER2 Positive Breast Cancer | Oncology | May 2029 |
| NCT06492616 | Elacestrant | Phase 3 | Breast Cancer | Oncology | Aug 2029 |
| NCT07222215 | Elacestrant | Phase 2 | Estrogen-receptor-positive Breast Cancer | Oncology | Dec 2029 |
| NCT05442216 | Tagraxofusp | Phase 2 | Acute Myeloid Leukemia | Oncology | Jul 2030 |
| NCT05512364 | Elacestrant | Phase 3 | ER-positive Breast Cancer | Oncology | Nov 2032 |
| NCT07242352 | Elacestrant | Phase 3 | Breast Cancer | Oncology | Sep 2033 |
Olema Pharmaceuticals CStone Pharmaceuticals Shenzhen TargetRx Lantheus Medical Imaging Day One Biopharmaceuticals
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.